Deals In Depth: May 2017
Executive Summary
AstraZeneca could pay up to $2.1 billion in an Anticalin protein therapeutics deal with Pieris, centered around respiratory diseases. In the latest CRO takeover, Thermo Fisher Scientific bought Patheon for $7.2 billion. Biopharma financing declined in May compared with April, mostly due to a decrease in public offering value.